drugset
drugset / Trial / NCT04855695

Avo In R/R And Previously Untreated MCL

NCT04855695 ↗

Phase 1/2 Recruiting 72 enrolled Austin I Kim AstraZeneca · collabRoche-Genentech · collab
NaSingle-groupOpen-labelTreatment

Summary

This research study is evaluating the combination of three drugs - acalabrutinib, venetoclax, and obinutuzumab - as a possible treatment for relapsed or refractory and untreated mantle cell lymphoma (MCL). The names of the study drugs involved in this study are: * Acalabrutinib * Venetoclax * Obinutuzumab

Timeline

Start
2021-07-02
Primary completion
2027-06-30
Completion
2027-12-31

Drugs

EvaluationDrugModalityDoseRoute
Subject Acalabrutinib Small molecule — Oral
Subject Obinutuzumab Monoclonal antibody — Intravenous
Subject Venetoclax Small molecule — Oral

Indications

mantle cell lymphoma